# Inclusion Going Forward - the NIH View/Approach

#### Marie A. Bernard, MD

Deputy Director
National Institute on Aging
Co-Chair, Trans-NIH Inclusion Governance Committee



## "Sunshine is the best disinfectant"

- Louis Brandeis

Former Associate Justice, SCOTUS





## Annonymized Individual Level Data

#### In applications or proposals:

Include an Inclusion plan

Submit a plan for including individuals across the lifespan

If excluding based on age, provide rationale and justification for the specific age range\*

#### In progress reports:

Report age at enrollment


The policy requires the age of participants at enrollment, sex/gender, and race/ethnicity be included in reports.

Age at enrollment may be reported to NIH in units ranging from hours to years.

Remember: Scientific Review Groups (SRGs) will assess each application/proposal as being "acceptable" or "unacceptable" with regard to the age-appropriate inclusion or exclusion of individuals in the research project.




## **Aggregate Demographic Reporting in RCDC**






## **Aggregate Demographic Reporting in RCDC**

#### Based on total NIH human subject studies enrolled in FY2018 projects





Source: NIH RCDC Inclusion Statistics Report



N= 3,238,207

## **Enhancement of Valid Analysis Policy**

Amendment: NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research

#### Purpose

This Notice amends NOT-OD-02-001. The purpose of this Notice is to inform the research community that NIH is amending its NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research to include a requirement that recipients conducting applicable NIH-defined Phase III clinical trials ensure results of valid analyses by sex/gender, race, and/or ethnicity are submitted to Clinicaltrials.gov. All other aspects of the NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research remain unchanged.

 Recipients conducting applicable NIH-defined Phase III trials must conduct and report analyses by sex/gender, race, and or ethnicity in CT.gov

(NOT-OD-18-014, 2017)



## **Final Research Performance Progress Report Policy**

- Final RPPR required for any grant that is terminated and any award that will not be extended, applies as of January 2017 (NOT-OD-17-022)
- Public posting of project outcomes policy applies to all final RPPRs submitted as of October 1, 2017 (NOT-OD-18-103)







#### **NIH GRANTS POLICY STATEMENT**

REVISED DECEMBER 2019. This document applies to all NIH grants and cooperative agreements for budget periods beginning on or after *October 1, 2019.* 

You are here: 8 Administrative Requirements > 8.6 Closeout > 8.6.2 Final Progress Report

Search NIH Grants Policy

#### 8.6.2 Final Research Performance Progress Report

A Final RPPR required for any grant that is terminated and any award that will not be extended through award of a new competitive segment. If a competitive renewal (Type 2) application has been submitted, the recipient must submit an Interim-RPPR while their renewal application is under consideration. In the event that the Type 2 is funded, NIH will treat the Interim-RPPR as the annual performance report for the final year of the previous competitive segment. If the Type 2 is not funded, the Interim RPPR will be treated by NIH staff as the institution's Final RPPR.

A Final RPPR should be prepared in accordance with the requirements in the RPPR Instructions found on the NIH RPPR website and any specific requirements set forth in the terms and conditions of the award. In addition to the standard requirements detailed in those Instructions, recipients should also report additional information required by the awarding IC in program-specific final progress report instructions.

Final RPPR Instructions for SBIR/STTR Phase II Reports are in Section 7.3. of the RPPR Instructions.

(NIH Grants Policy Statement 8.6.2, 2019)



### **Diversity Collaboration with CTTI**

- Develop resources to demonstrate the value of
  - increasing diversity in clinical trials and
  - adopting practices that include diverse patient populations in the development process for drugs and devices.




## **Inclusion Across the Lifespan**

### NIH's 2<sup>nd</sup> Inclusion Across the Lifespan (IAL-II) Workshop

https://www.nia.nih.gov/Inclusion-Across-Lifespan-2020

The workshop will be held virtually and is free of charge.



September 2<sup>nd</sup>, 2020

Registration open through September 1<sup>st</sup>, 2020.







Turning
Discovery Into
Health